Q4 2022 Results
Company overview
Financial review
Innovation: Pipeline overview
2023 expected key events
Regulatory
decisions
Cosentyx® HS
CosentyxⓇ 2 ml Al
Cosentyx® IV
Leqvio® Hypercholesterolemia
Submissions
Iptacopan PNH (US/EU/JP)
PluvictoⓇ mCRPC, pre-taxane (US)
Readouts
KisqaliⓇ HR+/HER2- BC (adj)
Iptacopan IgAN Ph3
Ph3 starts
Iptacopan C3G Ph3
Iptacopan in IC-MPGN
LeqvioⓇ CVRR primary prevention
lanalumab in immune thrombocytopenia
lanalumab in systemic lupus erythematosus
2023 priorities
Appendix
Innovation: Clinical trials
Abbreviations
H1 2023
H2 2023
EU
US
US
US
JP, China
US/EU
JP
Ph3
Ph3
Ph3
US
NATALEE Ph3 FIR
APPLAUSE-IgAN Ph3
Ph3 APPEAR-C3G Ph3
Ph3
HS hidradenitis suppurativa. PNH - paroxysmal nocturnal hemoglobinuria. mCRPC metastatic castration-resistant prostate cancer. FIR - first interpretable results. IgAN-immunoglobulin A nephropathy.
C3G complement 3 Glomerulopathy. IC-MPGN - immune complex membranoproliferative glomerulonephritis.
51 Investor Relations | Q4 2022 Results
INNOVATION
U NOVARTIS | Reimagining MedicineView entire presentation